Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double Blinded, Active Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL Admixed With Bupivacaine vs. Bupivacaine Only Administered as Combined Sciatic (in Popliteal Fossa) and Adductor Canal Nerve Block for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries
Conditions
Interventions
EXPAREL 13.3Mg/mL Suspension for Injection
Bupivacaine Hydrochloride
Start Date
June 15, 2020
Primary Completion Date
September 1, 2020
Completion Date
September 1, 2020
Last Updated
August 13, 2020
NCT04715139
NCT06486753
NCT04713098
NCT03782298
NCT05773846
NCT05087914
Lead Sponsor
Pacira Pharmaceuticals, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions